Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,720.68
(
0.32%
)
US TECH 100
24,136.00
(
0.50%
)
Dow Jones
47,065.45
(
0.25%
)
Brent Oil
99.55
(
1.27%
)
Bitcoin
74,136.23
(
-0.95%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 80699

Thursday, 04/01/2010 9:29:48 PM

Thursday, April 01, 2010 9:29:48 PM

Post# of 257251
Survey of 200 rheumatologists shows BMY’s Orencia is outdueling Actemra, Simponi, and Cimzia in the RA second-line biologic setting (i.e. the third-line setting overall, following methotrexate in the first line and Humira, Enbrel, or Remicade in the second line):

http://finance.yahoo.com/news/Orencia-Early-Leader-Among-prnews-2333906830.html?x=0&.v=1

Comments?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now